GO28141(vemurafenib + cobimetinib)


Protocolnummer:
EudraCT Number: 2012-003008-11 - gesloten

Ziekenhuizen:
GO28141(vemurafenib + cobimetinib)

Titel:
A phase lll, double-blind, placebo-controlled study of vemurafenib versus vemurafenib plus GDC-0973 in previously untreated BRAF V600-mutation patients with unresectable locally advanced or metastatic melanoma

Behandeling:
> Vemurafenib 960mg bd + placebo versus vemurafenib 960mg bd + GDC-0973 (cobimetinib) 60mg.

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: naïve to treatment: previous adjuvant immunotherapy is allowed, positive BRAF V600- mutation, measurable disease per RECIST v1.1. Ex: palliative radiotherapy within 14 days, uncontrolled glaucoma, hypertriglyceridemia, hyperglycemia, cardiac dysfunction, history of malabsorption, active CNS lesions.

Contactpersoon:

Alle trials